In patients with an RAS (p < 0.001) or BRAF (p < 0.001) mutation at the tumor/tumor stroma transition point, significantly lower percentages of the TPS are present compared to the CPS, whose percentage is significantly larger. This evidence concerns the gene BRAF and neoplasm.